Literature DB >> 26269412

The multi-kinase inhibitor pazopanib targets hepatic stellate cell activation and apoptosis alleviating progression of liver fibrosis.

Mahmoud Elshal1, Nashwa Abu-Elsaad2, Amr El-Karef3, Tarek Mostafa Ibrahim4.   

Abstract

Tyrosine kinase inhibitors have been emerged recently as an effective therapy against liver fibrosis. The current study was designed to test a potential anti-fibrotic effect of the multi-targeted receptor tyrosine kinase inhibitor pazopanib. Carbon tetrachloride (CCl4; 1 mL/kg) was injected intraperitoneally (i.p.) twice/week for 8 weeks. Pazopanib (10 and 30 mg/kg, i.p.) was administered three times/week at the beginning of week 5. Levels of liver function biomarkers (alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin, and total bilirubin), malondialdehyde, transforming growth factor-β1 (TGF-β1), caspase-3, factor-related apoptosis (FAS), vascular endothelial growth factor (VEGF) receptor-1, and pigment endothelial derived factor (PEDF) were measured. The tissue level of the inflammatory cytokines IL-6 and tumor necrosis factor-α (TNF-α) were assigned. Fibrotic area was measured by morphometry and expression of alpha-smooth muscle actin (α-SMA), caspase-3, platelet-derived growth factor (PDGF) receptor-β, and matrix metalloproteinase-2 (MMP-2) was scored immunohistochemically. Hepatic expression of collagen-1-alpha-1 (Col1A1) and tissue inhibitor metalloproteinase-1 (TIMP-1) mRNA were assigned by RT-qPCR. Injection of CCl4 resulted in marked collagen deposition, necroinflammation, and fibrosis (2.67%). Pazopanib in a dose of 30 mg/kg improved liver function, reduced fibrosis (1.48%), and decreased significantly (P < 0.01) liver expression of malondialdehyde, TGF-β1, IL-6, TNF-α, Col1A1, TIMP-1, α-SMA, MMP-2, PDGF receptor-β, and VEGF receptor-1. Additionally, the apoptotic markers (caspase-3, FAS) and the anti-angiogenic factor PEDF were upregulated significantly (P < 0.05). Pazopanib at a certain dose level can halt liver fibrosis progression through modulating inflammatory cytokines, suppressing stellate cell activity, inducing apoptosis, and potentially regulating angiogenesis.

Entities:  

Keywords:  Apoptosis; Liver fibrosis; PEDF; Pazopanib; Receptor tyrosine kinases

Mesh:

Substances:

Year:  2015        PMID: 26269412     DOI: 10.1007/s00210-015-1157-7

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  54 in total

Review 1.  Cirrhosis reversal: a duel between dogma and myth.

Authors:  Valeer J Desmet; Tania Roskams
Journal:  J Hepatol       Date:  2004-05       Impact factor: 25.083

2.  Contribution of Myofibroblasts of Different Origins to Liver Fibrosis.

Authors:  Michel Fausther; Elise G Lavoie; Jonathan A Dranoff
Journal:  Curr Pathobiol Rep       Date:  2013-09

3.  Apoptosis in chronic viral hepatitis parallels histological activity: an immunohistochemical investigation using anti-activated caspase-3 and M30 cytodeath antibody.

Authors:  Jo L McPartland; Muna Ali Guzail; Charles H Kendall; James Howard Pringle
Journal:  Int J Exp Pathol       Date:  2005-02       Impact factor: 1.925

4.  Sirius red histophotometry and spectrophotometry of sections in the assessment of the collagen content of liver tissue and its application in growing rat liver.

Authors:  J James; K S Bosch; D C Aronson; J M Houtkooper
Journal:  Liver       Date:  1990-02

5.  Novel role of gp91(phox)-containing NAD(P)H oxidase in vascular endothelial growth factor-induced signaling and angiogenesis.

Authors:  Masuko Ushio-Fukai; Yan Tang; Tohru Fukai; Sergey I Dikalov; Yuxian Ma; Mitsuaki Fujimoto; Mark T Quinn; Patrick J Pagano; Chad Johnson; R Wayne Alexander
Journal:  Circ Res       Date:  2002-12-13       Impact factor: 17.367

6.  Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis.

Authors:  Dominique Thabut; Chittaranjan Routray; Gwen Lomberk; Uday Shergill; Kevin Glaser; Robert Huebert; Leena Patel; Tetyana Masyuk; Boris Blechacz; Andrew Vercnocke; Erik Ritman; Richard Ehman; Raul Urrutia; Vijay Shah
Journal:  Hepatology       Date:  2011-06-26       Impact factor: 17.425

7.  Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of vascular endothelial growth factor receptor 1.

Authors:  Jun Cai; Wen G Jiang; Maria B Grant; Mike Boulton
Journal:  J Biol Chem       Date:  2005-12-08       Impact factor: 5.157

Review 8.  Fibrosis and cirrhosis reversibility - molecular mechanisms.

Authors:  Roben G Gieling; Alastair D Burt; Derek A Mann
Journal:  Clin Liver Dis       Date:  2008-11       Impact factor: 6.126

9.  Role of endothelial nitric oxide synthase in the development of portal hypertension in the carbon tetrachloride-induced liver fibrosis model.

Authors:  Nicholas G Theodorakis; Yining N Wang; Jian-Ming Wu; Mary A Maluccio; James V Sitzmann; Nicholas J Skill
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-07-23       Impact factor: 4.052

10.  VEGF signaling through NADPH oxidase-derived ROS.

Authors:  Masuko Ushio-Fukai
Journal:  Antioxid Redox Signal       Date:  2007-06       Impact factor: 8.401

View more
  2 in total

1.  Easy-to-use strategy for reference gene selection in quantitative real-time PCR experiments.

Authors:  Stefanie Klenke; Kristina Renckhoff; Andrea Engler; Jürgen Peters; Ulrich H Frey
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-09-20       Impact factor: 3.000

Review 2.  Repurposing of Kinase Inhibitors for Treatment of COVID-19.

Authors:  Ellen Weisberg; Alexander Parent; Priscilla L Yang; Martin Sattler; Qingsong Liu; Qingwang Liu; Jinhua Wang; Chengcheng Meng; Sara J Buhrlage; Nathanael Gray; James D Griffin
Journal:  Pharm Res       Date:  2020-08-10       Impact factor: 4.580

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.